Heron Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Heron Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Heron Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Heron Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Heron Therapeutics Inc (Heron) is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from various types of cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, that improves the therapeutic profile of injectable pharmaceuticals. The company's marketed products include Cinvanti for chemotherapy-induced nausea and vomiting (CINV) prevention; Aponvie for the prevention of postoperative nausea and vomiting (PONV) in adults; Sustol, an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy (MEC); and Zynrelef for the treatment of somatic postoperative pain from small to medium-sized surgical wounds in adults. Heron is headquartered in Cary, North Carolina, the US.
Headquarters
United States of America
Address
Suite 300, 25 Fenton Main Street, Cary, North Carolina, 27511
Website
www.herontx.com
Telephone
1 858 2514400
No of Employees
128
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HRTX (NASD)
Revenue (2024)
$154.9M
7.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-48.7%
(2024 vs 2023)
Market Cap*
$93.4M
Net Profit Margin (2024)
XYZ
-38.6%
(2024 vs 2023)
* As of and is in US$
Heron Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Sustol: | Aponvie |
| Chemotherapy-Induced Nausea and Vomiting | Cinvanti |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In May, the company entered into a settlement agreement with Mylan Pharmaceuticals to resolve ongoing patent litigations in the U.S. District Court for Delaware concerning CINVANTI and APONVIE injectable emulsions. |
| 2024 | Plans/Strategy | In December, the company announced its plans to relocate its headquarters from San Diego, California to Cary, North Carolina, the US. |
| 2024 | Regulatory Approval | In September, the company received approval from the U.S. Food and Drug Administration for the supplement application for ZYNRELEF (bupivacaine and meloxicam) Vial Access Needle (VAN). |
Competitor Comparison
| Key Parameters | Heron Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Takeda Pharmaceutical Co Ltd | Eisai Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | Japan |
| City | Cary | Rahway | New York City | Chuo-Ku | Bunkyo-Ku |
| State/Province | North Carolina | New Jersey | New York | Tokyo | Tokyo |
| No. of Employees | 128 | 75,000 | 75,000 | 47,029 | 10,543 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Adam Morgan | Chairman | Executive Board | 2023 | 46 |
| Craig Collard | Chief Executive Officer; Director | Executive Board | 2023 | 60 |
| Ira Duarte | Chief Financial Officer; Executive Vice President | Senior Management | 2023 | 57 |
| Mark Hensley | Chief Operating Officer | Senior Management | 2025 | - |
| William Forbes | Chief Development Officer; Executive Vice President | Senior Management | 2023 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer